Study of SHR-A2102 and Adebrelimab for muscle-invasive bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a combination of two drugs, SHR-A2102 and Adebrelimab, for people with muscle-invasive bladder cancer that hasn't spread. The goal is to see if this treatment can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have muscle-invasive bladder cancer that hasn't spread to other parts of the body.
- You are generally able to care for yourself (ECOG score 0 or 1) and expected to live at least 2 years.
- You have at least one tumor that can be measured by scans.
- Your major organs (kidneys, liver, heart, etc.) are working well enough.
- You haven't had any other cancer, serious infections, or heart problems recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combined with other anti-cancer drugs for advanced breast cancer. The goal is to see if the combination can shrink tumors and help people live longer, and if it is safe.
This trial tests two investigational drugs given together to treat high-risk non-muscle invasive bladder cancer that cannot be completely removed with standard surgery. The goal is to see if this combination can help control the cancer and avoid the need for bladder removal.
This study tests a new drug, SHR-2005, given directly into the bladder through a catheter. It is for people with intermediate- or high-risk bladder cancer that hasn't spread into the muscle, and aims to see if it is safe and how well it works.
This trial tests a new drug called SHR-A2102, which is a type of targeted therapy (an antibody-drug conjugate) for advanced urothelial carcinoma (bladder cancer). It may help if your cancer has not responded to standard treatments or if you are starting treatment for advanced disease.
This trial tests a new combination of two medications, SHR-A2102 and adebrelimab, for people with advanced bladder cancer that has not been treated before. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of two drugs, SHR-A2102 and Adebrelimab, with or without other treatments, for people with advanced or metastatic non-small cell lung cancer that cannot be removed by surgery or cured with radiation. It aims to see if this approach can shrink tumors or slow the cancer's growth.
Hear when a new Muscular Invasive Bladder Cancer (MIBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.